New Press Releases

6 January 2012
CMP Therapeutics gains CE mark for Novel Rhinitis product - Atlantic Secret™.

Download PDF

Previous Press Releases

29 July 2010
CMP Therapeutics Ltd (CMPT) announces the appointment of Dr Neill Moray Mackenzie as CEO and the injection of a € 1.5 million convertible loan from Inventages Venture Capital.

Download PDF


31 January 2006

CMP Therapeutics Ltd (CMPT) announces completion of € 4.5 million series A funding round to develop a treatment for respiratory allergies.

Download PDF



Scientific Publications

Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy.
P. Strong, H.Clark, K.Reid. Clin Exp Allergy 2002; 32 : 1794n -1800


Download PDF


Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
Hideki Hasegawa, Takeshi Ichinohe, Peter Strong, Izumi Watanabe, Satoshi Ito, Shin-ichi Tamura, Hiehiro Takahashi, Hirofumi Sawa, Joe Chiba, Takeshi Kurata, Tetsutaro Sata. J. Medical Virology, 2005; 75, 130 - 136

Download PDF


Treatment with chitin microparticles is protective against lung histopathology in a murine asthma model.
C. Ozdemir, D. Yazi, M. Aydogan, T. Akkoc, N. N. Bahceciler, P. Strong , and I. B. Barlan

Download PDF


Prophylactic Effects of Chitin Microparticles on Highly Pathogenic H5N1 Influenza Virus
Takeshi Ichinohe, Noriyo Nagata, Peter Strong, Shin-ichi Tamura, Hidehiro Takahashi, Ai Ninomiya, Masaki Imai, Takato Odagiri, Masato Tashiro, Hirofumi Sawa, Joe Chiba, Takeshi Kurata, Tetsutaro Sata, and Hideki Hasegawa

Download PDF




 


To discuss partnership opportunities contact Dr Neill Moray Mackenzie